Metastatic DTC
Conditions
Brief summary
Evaluation of complete response (CR) rate on soft tissue metastases after a maximum of two radioiodine administrations optimized with personalized pre-treatment dosimetry based on 124I-PET/CT. The response will be considered 6 months [1] after the last optimized administration, as a combination of evaluations (RECIST, 124I-PET/CT, 18F-FDG, and thyroglobulin).
Detailed description
Assessment of acute toxicity rate and severity, Assessment of the association among pre-treatment glucose metabolism, 124I uptake and therapy response, Assessment of the association among genetic mutations on cancer tissue, pre- and post-treatment miRNA expression, pre- and post-treatment glucose metabolism, iodine uptake, and 131I therapy response
Interventions
Sponsors
Fondazione IRCCS Istituto Nazionale Dei Tumori
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of complete response (CR) rate on soft tissue metastases after a maximum of two radioiodine administrations optimized with personalized pre-treatment dosimetry based on 124I-PET/CT. The response will be considered 6 months [1] after the last optimized administration, as a combination of evaluations (RECIST, 124I-PET/CT, 18F-FDG, and thyroglobulin). | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of acute toxicity rate and severity, Assessment of the association among pre-treatment glucose metabolism, 124I uptake and therapy response, Assessment of the association among genetic mutations on cancer tissue, pre- and post-treatment miRNA expression, pre- and post-treatment glucose metabolism, iodine uptake, and 131I therapy response | — |
Countries
Italy
Outcome results
None listed